SEC Form 4 · accession 0001104659-19-005520

Nabriva Therapeutics plc · NBRV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Gen Counsel & Corp Secretary

Period of report

Jan 31, 2019

Accepted (ET)

Feb 4, 2019 · 4:06 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001641640

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options^F1,F2	—	Jan 31, 2019	A	138,200	A	—	Jan 31, 2029	Ordinary Shares	138,200	138,200	D
Restricted Stock Units^F3,F4	—	Jan 31, 2019	A	52,500	A	—	Jan 31, 2023	Ordinary Shares	52,500	52,500	D

F1The exercise price is $1.90 per share.
F2This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
F3The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units.
F4The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period.